SOURCE: MBio Diagnostics, Inc.
BOULDER, CO--(Marketwired - May 5, 2014) - MBio Diagnostics, Inc. announced today it was awarded U.S. Patent No. 8,697,435, entitled "Integrated Sample Preparation and Analyte Detection," which extends the scope of the MBio LightDeck® planar waveguide technology. MBio Diagnostics is developing simple solutions for the in vitro diagnostics and life sciences markets, with specific focus on rapid, easy-to-use tests that generate laboratory-quality tests. The MBio platform is unique in its ability to provide answers for multiple disease markers using a single small sample, such as a drop of blood. Because of the low cost to manufacture and compatibility with different sample types, the technology is finding applications in global health, research, and industrial applications.
MBio's new patent covers a unique approach to the integration of sample preparation and detection. By combining this technique with MBio's proprietary LightDeck® planar waveguide technology, the system enables highly multiplexed, sensitive, rapid results. In contrast, traditional high-sensitivity tests require long incubation times to achieve high sensitivity, and often an assay can only detect one analyte at a time. According to MBio CTO Michael J. Lochhead, "This integrated method enables a fast, simple workflow that provides multiple results from a single sample -- a unique combination of speed and performance."
MBio Diagnostics, Inc. (www.mbiodx.com) is a privately held diagnostics and life sciences company based in Boulder, CO. MBio Diagnostics is increasing access to quality healthcare by delivering high sensitivity multiplexed tests with the speed and simplicity typical of point-of-care tests. The MBio System is initially being commercialized to manage treatment of HIV patients from a single drop of blood. The MBio detection system is being developed for a broad menu of applications including multiplex assays and cellular analysis.